MAG 200

Drug Profile

MAG 200

Alternative Names: MAG200

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Magellan Biologicals
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Osteoarthritis

Most Recent Events

  • 01 Aug 2017 Magellan Biologicals plans a phase I trial for Osteoarthritis in Australia, in November 2017 (ACTRN12617001095358p)
  • 12 Jul 2017 Preclinical trials in Osteoarthritis in Australia (Intra-articular) (ACTRN12617001095358p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top